Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29234150 | 0.92 | USP2 (0.49) | TSPOALDH1A1KDM4ELMNAUSP2 | |
| SCHEMBL25299417 | 0.89 | POLB (0.49) | TSPOALDH1A1KDM4ELMNAUSP2 | |
| SCHEMBL29234154 | 0.88 | TSHR (0.46) | TSPOALDH1A1KDM4ELMNAUSP2 | |
| SCHEMBL25260100 | 0.86 | TSPO (0.46) | TSPOALDH1A1KDM4ELMNAUSP2 | |
| SCHEMBL29234160 | 0.86 | GAA (0.46) | TSPOALDH1A1KDM4ELMNAUSP2 | |
| SCHEMBL29234153 | 0.86 | HTR2A (0.54) | TSPOALDH1A1SMN1; SMN2HTTSIGMAR1 | |
| SCHEMBL25263528 | 0.84 | MMP9 (0.50) | TSPOALDH1A1LMNATSHRSMN1; SMN2 | |
| SCHEMBL30945868 | 0.82 | HSD17B10 (0.50) | TSPOALDH1A1KDM4ELMNAUSP2 | |
| SCHEMBL30945864 | 0.81 | SLC2A1 (0.46) | TSPOALDH1A1KDM4ELMNATSHR | |
| SCHEMBL25261076 | 0.81 | SLC2A1 (0.46) | TSPOALDH1A1KDM4ELMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099423-A1 | PIPERAZINE-BASED AGONISTS OF LFA-1 AND VLA-4 | TEXAS HEART INSTITUTE (US) | 2025-03-27 | — | — | US | claimed |
| CN-117980302-A | Piperazine-based agonists of LFA-1 and VLA-4 | 德克萨斯心脏研究所 | 2024-05-03 | — | — | CN | claimed |
| WO-2023018471-A9 | PIPERAZINE-BASED AGONISTS OF LFA-1 AND VLA-4 | TEXAS HEART INSTITUTE (US) | 2023-07-13 | — | — | WO | claimed |
| US-20250099423-A1 | PIPERAZINE-BASED AGONISTS OF LFA-1 AND VLA-4 | TEXAS HEART INSTITUTE (US) | 2025-03-27 | — | — | US | disclosed |
| CN-117980302-A | Piperazine-based agonists of LFA-1 and VLA-4 | 德克萨斯心脏研究所 | 2024-05-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099423-A1 | PIPERAZINE-BASED AGONISTS OF LFA-1 AND VLA-4 | ITGA4, VCAM1, ITGB4 | TSPO 984/4885ALDH1A1 339/4885KDM4E 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.